Abstract
Activation of the angiotensin-converting enzyme (ACE)/angiotensin II (Ang II)/angiotensin type-1 receptor (AT1) axis in the heart and vasculature plays an important role in the development of diabetic complications. The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis has been shown to oppose the actions of Ang II. Our results have shown that chronic treatment with Ang-(1-7) led to correction of the altered responses to norepinephrine or endothelin-1 and carbachol in the mesenteric bed, carotid, and renal arteries of diabetic rats and improved recovery of left ventricular function from 40 min of global ischemia. We showed that the beneficial effects of Ang-(1-7) on the diabetic vasculature involve inhibition of the detrimental EGFR/ERK1/2/p38MAP kinase pathway. Ang-(1-7) treatment inhibited cardiac NADPH oxidase (NOX) and cardiac nuclear factor-κB (NF-κB) activity and also suppressed the expression of several pro-inflammatory genes involved in the NF-κB signaling pathway, including complement component 3 (C3), interleukin 1-beta (Il-1β), interleukin 6 (Il-6), NACHT-containing protein (Nalp12), and caspase 1 (Casp1). We conclude that activation of the Ang-(1-7)-mediated signal transduction pathway appears to be an important therapeutic strategy to reduce cardiovascular events in diabetic patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564
Scully T (2012) Diabetes in numbers. Nature 485:S2–S3
Whiting DR, Guariguata L, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321
Von-Lueder TG, Krum H (2012) RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther 2:171–179
Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93:137–188
Patel VB, Bodiga S, Basu R et al (2012) Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res 110:1322–1335
Aneja A, Tang WH, Bansilal S (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121:748–757
Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213–3223
Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543–567
Benter IF, Diz DI, Ferrario CM (1993) Cardiovascular actions of angiotensin-(1-7). Peptides 14:679–684
Benter IF, Diz DI, Morris M, Ferrario CM (1995) Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 269:H313–H319
Benter IF, Diz DI, Ferrario CM (1995) Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 26:1138–1144
Benter IF, Yousif MHM, Anim JT et al (2006) Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats-treated with L-NAME. Am J Physiol Heart Circ Physiol 290:H684–H691
Crackower MA, Sarao R, Oudit GY et al (2002) Angiotensin converting enzyme 2 is an essential regulator of heart function. Nature 417:822–828
Tikellis C, Pickering R, Tsorotes D (2012) Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. Clin Sci (Lond) 123:519–529
Kassiri Z, Zhong J, Guo D et al (2009) Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2:446–455
Stewart JA, Lazartigues E, Lucchesi PA (2008) The angiotensin converting enzyme 2/Ang-(1-7) axis in the heart: a role for MAS communication? Circ Res 103:1197–1199
Nakamura K, Koibuchi N, Nishimatsu A et al (2008) Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice. Hypertens Res 31: 1953–1961
Tallant EA, Clark MA (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42:574–579
Tallant EA, Ferrario CM, Gallagher PE (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol 289:H1560–H1566
Santos RAS, Simões e Silva AC, Maric C et al (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100:8258–8263
Santos RAS, Ferreira AJ, Pinheiro SV et al (2005) Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Invest Drugs 14:1019–1031
Santos RAS, Castro CH, Gava E et al (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47:996–1002
Pinheiro SV, Simões e Silva AC, Sampaio WO et al (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44:490–496
Benter IF, Yousif MH, Cojocel C et al (2007) Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292:H666–H672
Akhtar S, Benter IF (2013) The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. Bioimpacts 3:5–9
Avraham R, Yarden Y (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12:104–117
Higuchi S, Ohtsu H, Suzuki H et al (2007) Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112:417–428
Smith NJ (2011) Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy. Hypertension 57:973–980
Akhtar S, Yousif MH, Benter IF (2012) Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol 165: 1390–1400
Benter IF, Yousif MH, Griffiths SM et al (2005) Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br J Pharmacol 145:829–836
Benter IF, Yousif MH, Hollins AJ et al (2005) Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J Vasc Res 42:284–291
Benter IF, Benboubetra M, Hollins AJ et al (2009) Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vasc Pharmacol 51:236–245
Yousif MH, Benter IF, Akhtar S (2005) The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol 25:69–78
Belmadani S, Palen DI, Gonzalez-Villalobos RA et al (2008) Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 57:1629–1637
Galán M, Kassan M, Choi SK et al (2012) A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension 60:71–80
Al-Maghrebi M, Benter IF, Diz DI (2009) Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 59:263–268
Benter IF, Yousif MH, Dhaunsi GS et al (2008) Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 28:25–33
Dhaunsi GS, Yousif MH, Akhtar S et al (2010) Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities. Eur J Pharmacol 638:108–114
Yousif MH, Dhaunsi GS, Benter IF (2012) Characterization of angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol Res 66: 269–275
Acknowledgments
This work was supported by a grant from Kuwait University Research Sector (MR05/09).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Benter, I.F., Yousif, M.H.M., Juggi, J.S., Akhtar, S. (2014). The Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Axis: A Potential Target for Treating Diabetic Cardiovascular Disease. In: Turan, B., Dhalla, N. (eds) Diabetic Cardiomyopathy. Advances in Biochemistry in Health and Disease, vol 9. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9317-4_22
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9317-4_22
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9316-7
Online ISBN: 978-1-4614-9317-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)